Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 6/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.76 |
| ▸ | PYGL | P06737 | 8/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | F7 | P08709 | 1/20 | 0.63 |
| ▸ | F3 | P13726 | 1/20 | 0.63 |
| ▸ | GUSB | P08236 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398652 | 0.88 | NHERF1 (0.63) | NHERF1MEN1KMT2ARXFP1PYGL | |
| SCHEMBL6400080 | 0.84 | NHERF1 (0.58) | NHERF1MEN1KMT2ARXFP1PYGL | |
| SCHEMBL16627058 | 0.84 | NPC1 (0.78) | NHERF1MEN1KMT2ARXFP1PYGL | |
| SCHEMBL2760086 | 0.84 | NPC1 (0.73) | NHERF1MEN1KMT2ARXFP1NPC1 | |
| SCHEMBL29475123 | 0.83 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL7208136 | 0.83 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL5405858 | 0.83 | NHERF1 (0.67) | NHERF1MEN1KMT2ARXFP1PYGL | |
| SCHEMBL27385788 | 0.83 | NPC1 (0.71) | NHERF1MEN1KMT2ARXFP1PYGL | |
| SCHEMBL2735818 | 0.83 | NPC1 (0.71) | NHERF1MEN1KMT2ARXFP1NPC1 | |
| SCHEMBL14845689 | 0.83 | TP53 (1.00) | RXFP1NPC1RAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325326-A1 | METHOD OF TREATING PULMONARY FIBROSIS BY TARGETING GLYCOGEN UTILIZATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2024-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325326-A1 | METHOD OF TREATING PULMONARY FIBROSIS BY TARGETING GLYCOGEN UTILIZATION | GYS1, GYS2, AGL | NHERF1 1171/4885MEN1 4736/4885KMT2A 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.